In This Issue...

What's new in glaucoma treatment?

Editorial continues over page ➤

Glaucmataous optic neuropathy: splinter haemorrhages

Glaucoma treatment: the state of the evidence

Interventions for the treatment of different forms of glaucoma have been tried and tested for many years. The idea that lowering the pressure might be helpful was first proposed more than a hundred years ago. By the 1950s, it was established that raised intraocular pressure (IOP) was glaucoma, and vice versa. However, in the mid 1960s, Fred Hollows and Peter Graham demolished that simple concept by revealing that there were many people in the population with raised IOP but no glaucoma, and people with glaucoma without raised IOP. Nevertheless, IOP remains an important risk factor (and the only one we can modify) for a group of conditions characterised by a progressive atrophy of the optic nerve associated with typical structural and functional abnormalities.

Only quite recently has robust evidence emerged regarding the effectiveness of treatment for open-angle glaucoma (OAG). There is still uncertainty about the best way to manage chronic angle closure. This discussion focuses only on the primary glaucomas in adults, open-angle and acute, and chronic angle closure.

Richard Wormald
Co-ordinating Editor, Cochrane Eyes and Vision Group (CEVG), International Centre for Eye Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.

Editorial continues over page ➤
EDITORIAL

Continued

Open-angle glaucoma

The first major systematic review was by Rossetti et al. in 1993.1 Despite finding more than 120 randomised controlled trials (RCTs) of the medical treatment of open-angle glaucoma and ocular hypertension, the authors could not find good evidence that lowering IOP either prevented the development of glaucomatous optic nerve damage, or prevented its progression in established disease. Researchers complained that it would be impossible to randomly allocate patients with overt disease to a control group with no intervention or placebo; yet they had to confront the ethical reality that the effectiveness of treatment was uncertain. The ethical challenge was already being met by the collaborative normal tension glaucoma study.2 Many patients with this form of glaucoma were not routinely receiving treatment. Patients were recruited with OAG whose pressures were never found to be higher than 24 mm Hg. Patients were not randomly allocated to pressure-lowering intervention until they showed definite evidence of progression. About 40 per cent of participants did not progress in five years. This was an important observation on the natural history of the disease. Vision declined in both treated and untreated groups, and it was only after adjusting for the effect of cataract that a beneficial effect of lowering pressure could be demonstrated. Because some eyes deteriorated despite successful lowering of pressure, it was postulated that there existed mechanisms responsible for damage to the optic nerve, independent of pressure. Ocular hypertension (OHT) was another ethical loophole. Indeed, many patients with OHT were not normally treated, and there was uncertainty about whether lowering pressure would reduce the risk of developing nerve damage. The ocular hypertension treatment study (OHTS) was a multi-centre RCT based in the USA.3 Patients with raised pressure, but no definite nerve damage, were randomly allocated to treatment or none. Conversion rates were low in five years, but the study was large enough to detect a small treatment effect. It was possible to draw firm conclusions that there was a treatment benefit. The baseline risk of converting was small, about 10 per cent in five years. But treatment reduced this risk by half. The number of patients with OHT needed to treat (NNT) to prevent one from developing optic nerve damage, was about 15 for evidence of structural and/or functional damage, but 42 for functional damage only, i.e. new visual field loss.

The question remained about the effectiveness of lowering pressure in overt disease. The early manifesto glaucoma trial (EMGT)4 was designed to address this. To find 250 patients with glaucoma, it was necessary to screen more than 60,000 people in southern Sweden. Half of these patients were randomly allocated to treatment and the other half to none. Using a sensitive algorithm for detecting progression in automated threshold perimetry, the trial found a much larger treatment effect, an NNT of 7.

The difference between the treatment effect found in these two studies may reflect differences in the sensitivity of the methods used to detect change, but it can also be explained by differences in the participants. EMGT used a population-based sample identified on the basis of optic nerve head appearance and visual field abnormalities, independent of IOP (the mean IOP was 20 mm Hg for the whole trial sample). The OHTS included patients already in clinics with raised pressure but normal optic nerve. They were effectively selected for resistance to the effects of pressure on the optic nerve. OAG is a disease of the optic nerve in which it is vulnerable to the effects of pressure. The higher the pressure, the more likely it is that damage will occur, though the vulnerability of the nerve to pressure is a crucial determinant of disease risk.

A systematic review published in the British Medical Journal5 in 2005 summarises the evidence for the effectiveness of medical treatment in lowering IOP in OHT, normotensive glaucoma (NTG), and primary open-angle glaucoma (POAG). The lack of evidence highlighted by Rossetti et al. has now been addressed. More detail is needed on the effectiveness of different types of medical, laser and surgical treatments. A completed systematic review on medical versus surgical treatment6 has found that both treatments are equally effective. This is important evidence for the benefit of surgery where the feasibility of sustained medical therapy is unlikely. Two subsequent ongoing Cochrane reviews are examining the evidence for the different medical options and laser trabeculoplasty, both of which are due to be published within the next year.7,8

Angle-closure glaucoma

In angle closure and angle-closure glaucoma, there is less evidence of effectiveness of treatments. Useful definitions have been proposed for these conditions, in which anatomical abnormalities of the angle with or without raised IOP are associated from those that cause damage to the optic nerve.9 Most believe that the structural abnormalities of the anterior segment leading to higher (sometimes very high) pressure are more important than the vulnerability of the optic nerve, because almost every optic nerve will succumb to the effects of prolonged and excessive elevation of IOP in angle closure.

There is no doubt that in acute angle closure there is an urgent need to reduce IOP. There are different ways of doing this. Ideally, this should be done as quickly as possible, while minimising the risk of making the patient feel even worse. Intravenous osmotic agents such as glycerol or mannitol have fallen out of favour, but evidence regarding the safety and effectiveness of these kinds of interventions is almost entirely

Vol 19 No. 59 | September 2006

Community Eye Health Journal

Supporting VISION 2020: The Right to Sight

The journal is produced in collaboration with the World Health Organization

34 COMMUNITY EYE HEALTH JOURNAL | VOL 19 NO. 59 | SEPTEMBER 2006
‘There is a growing body of good evidence about the effectiveness of glaucoma treatments. An effective service for prevention of glaucoma blindness requires highly developed infrastructure, including fully integrated primary, secondary and tertiary eye care services’

Outcomes

Outcomes represent a great challenge in glaucoma since the aim of treatment is preserving sight in the long term. The natural history of the disease is as long as a clinician’s career, so it is inevitable that surrogate or proxy measures must be used. IOP has had to suffice for many short-term studies, but those asking the question about preserving sight must measure visual function. Progression, however measured, has become the key parameter, because we seek to reduce visual decay to a rate that is compatible with the patient’s sighted lifetime. It should be the primary outcome of any new trial. Harmful effects are of equal importance.

Conclusion

There is a growing body of good evidence about the effectiveness of glaucoma treatments. In terms of VISION 2020, deploying an effective service for prevention of glaucoma blindness requires highly developed infrastructure, including fully integrated primary, secondary and tertiary eye care services. This is an ideal far removed from reality for most poorer countries, and is not in place in many so-called developed countries, including the UK, where people still present too late, with advanced optic nerve damage and a poor prognosis for a sighted lifetime.

Many questions remain about the effectiveness of glaucoma treatment, but the most urgent need for evidence is for the best management of both acute and chronic angle-closure glaucoma. Some studies are underway but more are needed. Laser trabeculoplasty has been shown to be cheap and sometimes effective in trials. The use of the Diode laser, as a means of deferring the need for surgery in poorer countries, needs to be explored. In more affluent countries, a large trial is now needed to explore whether population-based screening for glaucoma can save sight.

References


ABSTRACT

The number of people with glaucoma worldwide in 2010 and 2020

Quigley HA, Bromman AT

Aim: To estimate the number of people with open-angle (OAG) and angle-closure glaucoma (ACG) in 2010 and 2020. Methods: A review of published data with use of prevalence models. Data from population-based studies of age-specific prevalence of OAG and ACG that satisfied standard definitions were used to construct prevalence models for OAG and ACG by age, sex, and ethnicity, weighting data proportional to sample size of each study. Models were combined with UN world population projections for 2010 and 2020 to derive the estimated number with glaucoma. Results: There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74 per cent will have OAG. Women will comprise 55 per cent of OAG, 70 per cent of ACG, and 59 per cent of all glaucoma in 2010. Asians will represent 47 per cent of those with glaucoma and 87 per cent of those with ACG. Bilateral blindness will be present in 4.5 million people with OAG and 3.9 million people with ACG in 2010, rising to 5.9 and 5.3 million people in 2020, respectively. Conclusions: Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians.